Skip to main content
Caplight Logo









Receptor Life Sciences

Receptor Life Sciences

Private
Seattle, WashingtonHealthcare & Life Scienceshttp://receptorlife.com/

Last Round

Series A

Extension

Apr 7, 2022

Total Funding Raised

$38.7M

Company Overview

Receptor Life Sciences is a pharmaceutical company that develops innovative therapies for central nervous system disorders using FDA-approved drug delivery technologies for cannabinoid products.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

cannabinoid therapeuticsdrug-device combinationCNS disorderscentral nervous systemdry powder inhalationbiopharmaceuticalcannabidiolCBD505(b)(2) pathwayclinical developmentpharma techdrug deliverymedical devicebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Receptor Life Sciences Comparables

Compare Receptor Life Sciences with similar companies based on industry and business-model similarity.

Receptor Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ANANDA Scientific
79%
UCB
76%
Synendos Therapeutics
71%

Receptor Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionApr 7, 2022
Series AOct 29, 2018

Receptor Life Sciences Investors

Notable investors and investment history

Receptor Life Sciences investors
InvestorRounds
Granite Point CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2022

    $9.7M round led by Granite Point Capital

  • Oct 29, 2018

    $29M round completed.

Receptor Life Sciences Filings

Explore SEC and related filing metadata, where available.

Receptor Life Sciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Receptor Life Sciences's valuation, stock price, and market status.

Is Receptor Life Sciences a public or private company?

Receptor Life Sciences is a private company.

What is the current stock price of Receptor Life Sciences?

Receptor Life Sciences is a private company with no public stock price. Caplight tracks Receptor Life Sciences's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Receptor Life Sciences worth (valuation)?

Valuation information for Receptor Life Sciences is not publicly available.

Can I buy Receptor Life Sciences stock?

Receptor Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Receptor Life Sciences's last funding round?

Receptor Life Sciences's most recent funding round was Series A Extension on April 7, 2022.

Who are the main investors in Receptor Life Sciences?

Key investors in Receptor Life Sciences include Granite Point Capital.

Will Receptor Life Sciences IPO soon?

No public IPO plans have been announced for Receptor Life Sciences.

How can I track Receptor Life Sciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Receptor Life Sciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Year Founded2015
Last FundingApr 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?